Table 1.
Extracted Data from All Included Studies
| Authors | Year | City, country | Prevalence of H. pylori infection in patients with CSR | Prevalence of H. pylori infection in the control group | Odds ratio (P-value) |
|---|---|---|---|---|---|
| Roshani et al. [21] | 2014 | Tehran, Iran | 30/35 (85.7%) | 76/138 (55.1%) | 4.895 (0.001) |
| Warrow et al. [23] | 2012 | New York, USA | 3/18 (16.7%) | ---- | ---- |
| Misiuk-Hojlo et al. [13] | 2009 | Wroclaw, Poland | 37/55 (67.0%) | 26/55 (47.0%) | 2.29 (<0.05) |
| Kmera-Muszynska et al. [18] | 2008 | Warszawie, Poland | 11/14 (78.5%) | ----- | ---- |
| Feghhi et al. [22] | 2008 | Ahvaz, Iran | 37/54 (68.5%) | 38/59 (65.0%) | 1.20 (0.64) |
| Asensio-Sanchez et al. [14] | 2008 | Valladolid, Spain | 11/16 (68.75%) | 6/20 (30.0%) | 5.13 (<0.05) |
| Cotticelli et al. [15] | 2006 | Napoli, Italy | 18/23 (78.2%) | 10/23 (43.5%) | 4.6 (<0.03) |
| Ahnoux-Zabsonre et al. [16] | 2004 | Côte d’Ivoire, France | 31/78 (39.7%) | Overall population of 58,419,710 inhabitants of France in 1999 (25.4%) | ---- |
| Mauget-Faysse et al. [2] | 2002 | Lyon, France | 9/16 (56.3%) | Historical control population (27.5%) | ---- |
H. pylori, Helicobacter pylori; CSR, central serous chorioretinopathy